Ramipril in the treatment of vascular diseases (Q36249938)

13 August 2017

1 reference

title

Ramipril in the treatment of vascular diseases (English)

1 reference

13 August 2017

1 reference

ChEBI release 2020-05-28

Michael J Rokoss

1

1 reference

PubMed ID

16144510

13 August 2017

Koon K Teo

series ordinal

2

1 reference

PubMed ID

16144510

13 August 2017

language of work or name

English

0 references

publication date

1 September 2005

1 reference

Expert Opinion on Pharmacotherapy

13 August 2017

1 reference

13 August 2017

6

1 reference

13 August 2017

11

1 reference

13 August 2017

1911-1919

1 reference

Ramipril. An updated review of its therapeutic use in essential hypertension and heart failure

13 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.11.1911

Ramipril for the prevention and treatment of cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.11.1911

Ramipril. A review of its pharmacological properties and therapeutic efficacy in cardiovascular disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.11.1911

Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.11.1911

Prevention of left ventricular hypertrophy by ACE-inhibitor, ramipril in comparison with calcium-channel antagonist, felodipine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.11.1911

Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.11.1911

Follow-up study of patients randomly allocated ramipril or placebo for heart failure after acute myocardial infarction: AIRE Extension (AIREX) Study. Acute Infarction Ramipril Efficacy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.11.1911

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.11.1911

Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE Substudy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.11.1911

Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.11.1911

Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.11.1911

Angiotensin-converting-enzyme inhibition in stable coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.11.1911

Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.11.1911

Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.11.1911

Ramipril and the development of diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.11.1911

Effects of captopril on glucose transport activity in skeletal muscle of obese Zucker rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.11.1911

Antihypertensive therapy with enalapril improves glucose storage and insulin sensitivity in hypertensive patients with non-insulin-dependent diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.11.1911

Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: the DREAM trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.11.1911

Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.11.1911

Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.11.1911

Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease. The Task Force on ACE-inhibitors of the European Society of Cardiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.11.1911

Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.11.1911

Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.11.1911

10.1517/14656566.6.11.1911

21 January 2018

Identifiers

DOI

1 reference

13 August 2017

1 reference

PubMed ID

16144510